Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment

Ann Oncol. 2000 Nov;11(11):1504. doi: 10.1023/a:1026555604250.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / therapeutic use
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / therapeutic use
  • Double-Blind Method
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / therapeutic use
  • Immunotherapy*
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use
  • Male
  • Melanocytes / pathology
  • Melanoma / classification
  • Melanoma / pathology*
  • Melanoma / therapy
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Neoplastic Stem Cells / pathology
  • Prognosis
  • Recombinant Proteins
  • Skin Neoplasms / classification
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / therapy
  • Treatment Failure

Substances

  • BCG Vaccine
  • Cancer Vaccines
  • Immunologic Factors
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins